Comparative Pharmacology
Head-to-head clinical analysis: EMVERM versus HETRAZAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMVERM versus HETRAZAN.
EMVERM vs HETRAZAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.
Diethylcarbamazine (HETRAZAN) sensitizes microfilariae to phagocytosis by immobilizing them and altering their surface, making them more susceptible to destruction by host immune cells. It also has anthelminthic activity against adult worms.
Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.
2 mg/kg orally three times daily after meals for 3 weeks (total dose 120 mg/kg per course). Maximum single dose: 10 mg/kg.
None Documented
None Documented
2-8 hours; clinical context: the short half-life supports once-daily dosing; metabolites may persist longer.
Terminal elimination half-life is 8-12 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily fecal (approx. 90%) as unchanged drug and metabolites; <10% excreted renally.
Renal excretion of unchanged drug accounts for approximately 50-60% of elimination; the remainder is metabolized hepatically with metabolites excreted in urine. Fecal elimination is minimal (<5%).
Category C
Category C
Anthelmintic
Anthelmintic